Matthew K. Fust - 19 Jul 2021 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
19 Jul 2021
Net transactions value
-$87,950
Form type
4
Filing time
20 Jul 2021, 17:00:32 UTC
Previous filing
13 Jul 2021
Next filing
27 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $9,550 +5,000 +40% $1.91* 17,536 19 Jul 2021 Direct F1
transaction CRNX Common Stock Sale $97,500 -5,000 -29% $19.50 12,536 19 Jul 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Non-qualified stock option (Right to Buy) Options Exercise $0 -5,000 -13% $0.000000 32,092 19 Jul 2021 Common stock 5,000 $1.91 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter.
F3 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $19.50. The range of sales prices on the transaction date was $19.50 to $19.52 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.